Collegium Pharmaceutical (NASDAQ:COLL) will be issuing its quarterly earnings data after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.42) by $0.02. The firm had revenue of $73.10 million for the quarter, compared to the consensus estimate of $72.21 million. Collegium Pharmaceutical had a negative net margin of 39.10% and a negative return on equity of 61.82%. The firm’s revenue for the quarter was up 1930.6% compared to the same quarter last year. On average, analysts expect Collegium Pharmaceutical to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ COLL opened at $15.47 on Tuesday. The company has a current ratio of 0.82, a quick ratio of 0.78 and a debt-to-equity ratio of 3.94. The firm has a market capitalization of $544.17 million, a P/E ratio of -6.26 and a beta of 0.24. Collegium Pharmaceutical has a 12 month low of $9.20 and a 12 month high of $29.90.
COLL has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, August 8th. BidaskClub downgraded shares of Collegium Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. HC Wainwright reaffirmed a “buy” rating on shares of Collegium Pharmaceutical in a research report on Monday, September 17th. Piper Jaffray Companies set a $34.00 target price on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, July 11th. Finally, Cantor Fitzgerald set a $35.00 target price on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, October 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $31.71.
In related news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Monday, October 15th. The shares were sold at an average price of $16.53, for a total transaction of $413,250.00. Following the completion of the sale, the director now owns 361,000 shares in the company, valued at approximately $5,967,330. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.87% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Collegium Pharmaceutical (COLL) Scheduled to Post Quarterly Earnings on Thursday” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/06/collegium-pharmaceutical-coll-scheduled-to-post-quarterly-earnings-on-thursday.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Recommended Story: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.